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Background: The objective of this study was to establish a new sandwich based enzyme linked immunosorbent
assay (ELISA) for measuring the protein mass of human hepatic triacylglyceride lipase (HTGL).
Method: Two mouse monoclonal antibodies raised against human HTGL were used for the sandwich ELISA. The
post-heparin plasma (PHP) samples obtained at a heparin dose of 50 unit/kg from 124 normolipidemic subjects
were used for this ELISA.
Results: The dynamic assay range of the developed ELISA for the HTGL was from 0.47 to 30 ng/ml. The CV was
b7% in both intra- and inter-assays, and it did not cross-react with lipoprotein lipase or endothelial lipase (EL).
The HTGL concentration in PHP showed a strong correlation with HTGL activity [n = 121, r = 0.778,
p b 0.001]. There was a weak relation of HTGL concentration against high-density lipoprotein cholesterol
(HDL-C) [n = 123, r = −0.229, p = 0.011] but no relations against total cholesterol (TC), low-density lipopro-
tein cholesterol (LDL-C), triglycerides (TG), small dense LDL, remnant like particles cholesterol (RLP-C) and
RLP-TG were conﬁrmed. Interestingly, a weak but positive correlation between HTGL concentration and EL
concentration was shown [n = 122, p = 0.013, r = 0.224].
Conclusion: These results indicate that this new sandwich ELISA for measuring HTGL concentration in PHP can
be applied in a daily clinical practice.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hepatic triglyceride lipase (HTGL), a lipolytic enzyme, is a se-
creted glycoprotein, and is synthesized by hepatocytes and bound
to heparin sulfate proteoglycans at the surface of liver sinusoidal
capillaries. HTGL plays a major role in lipoprotein metabolism as a
lipolytic enzyme that hydrolyzes triglycerides (TGs), phospho-
lipids in chylomicron remnants, intermediate-density lipoproteins
(IDLs) and high-density lipoproteins (HDLs) [1,2]. Patients with
HTGL deﬁciency present with hypercholesterolemia or hypertriglyc-
eridemia, and accumulate very-low-density lipoproteins (VLDLs),Medicine Kanazawa Medical
hikawa Prefecture 920-0293,
yashi).
rights reserved.chylomicron remnants, IDLs, TG-rich low-density lipoproteins (LDLs)
and HDLs [3–8].
Although there was a commercially available sandwich ELISA kit
that was developed in Japan [9] for measuring HTGL concentration
assay system using 2 distinct monoclonal antibodies raised against
human HTGL puriﬁed from post-heparin plasma (PHP) as a starting
material, it was withdrawn from the market with unknown reasons
almost a decade ago. Since no high sensitive assay system for mea-
suring the protein concentration in plasma was available, we
reported on an easy and quick PHP–HTGL activity assay system sev-
eral years ago [10,11]. But we believe that it is still important to
determine quantity of HTGL concentration in order to understand
the clinical signiﬁcance of this enzyme in lipoprotein metabolism,
especially in the case of detecting dysfunctional types of HTGL.
We have now established a new sandwich ELISA method using 2 dis-
tinct monoclonal antibodies which are raised against puriﬁed human
HTGL from a concentrated conditioned medium of human HTGL-471
transfected Chinese hamster ovary (CHO) cells.
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Fig. 1. Quantiﬁcation of puriﬁed human HTGL protein and immunoblotting analysis. We quantiﬁed the puriﬁed Flag tagged HTGL-471 protein from the concentrated conditioned
medium of human HTGL-471/CHO 3B1 using an anti-FLAG M2 afﬁnity gel and sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE, right side) followed by stain-
ing with Coomassie Brilliant Blue (left side). The purity of the recombinant human HTGL protein was determined at the concentration of 17 μg/ml by densitometry using a Multi
gauge and the concentration of the protein was determined by comparison with BSA as an indicator.
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2.1. Preparation of puriﬁed HTGL
The puriﬁed humanHTGLwas prepared as previously reported [12].
We generated recombinant human HTGL as follows. A full-length of
human HTGL cDNA was identiﬁed in human liver cDNA (Clonetech)
by PCR using primers in which a FLAG-epitope tag was added to the 3′
end of cDNA before sub-cloning. To generate the plasmid encoding
hHTGL-Full, the cDNA was inserted into pcDNA3.1(+) expression
vector (Invitrogen). However, human HTGL is exhibited on cell surface
through the binding of 5′ carboxyl-terminal residues (KRKIR) [12].
Therefore, we also prepared a truncated human HTGL mutant
(hHTGL-471) this time by using deleted 5′ carboxyl terminal residues
in order to promote its secretion in culture supernatant. Then, we
used antisense PCR primers for generating the plasmids encoding
hHTGL-Full and hHTGL-471, respectively. Each PCR product was
inserted into pcDNA3.1(+) expression vector after a FLAG-epitope tag
was added to the 3′ end. CHO cells were transfected with the
hHTGL-Full plasmid or the hHTGL-471 plasmid and selected with
500 μg/ml of G418 for establishing of stable transfectants. Next, we
screened the transfectants by detecting the expression of hHTGL-Full
or hHTGL-471 expression with anti- c-FLAG rabbit IgG (Immuno-
Biological Laboratories) and selected the high-expression clones as a
human HTGL-Full-Flag/CHO named as 8A4 or human HTGL-471-Flag/
CHO named as 3B1, respectively. We puriﬁed HTGL protein from the
concentrated conditioned medium of human HTGL-471-Flag/CHO 3B1
using an anti-FLAG M2 afﬁnity gel (Sigma-Aldrich). We estimated the
purity of the recombinant human HTGL protein using the Multi GaugeTable 1
Clinical proﬁle of the study subjects.
Age, y 26.4 ± 6.1
Body mass index, kg/m2 25.0 ± 3.7
Men/women 67/57
Total cholesterol, mg/dl 163 ± 30
Triglycerides, mg/dl 57.2 ± 37.3
HDL-cholesterol, mg/dl 48.5 ± 11.8
LDL-cholesterol, mg/dl 93.3 ± 26.4
sdLDL, mg/dl 26.7 ± 12.7
RLP-cholesterol, mg/dl 4.1 ± 2.1
RLP-triglycerides, mg/dl 7.1 ± 10.6densitometry and determined the concentration of the protein by com-
parison with bovine serum albumin (BSA) as an indicator after electro-
phoresis (Fig. 1).2.2. Preparation of monoclonal antibody (MoAb)
The monoclonal antibody for human HTGL was prepared as
reported previously [10]. In brief, we used the puriﬁed HTGL protein
which was emulsiﬁed with Freund complete adjuvant for ﬁrst immu-
nization and then immunized it with Freund incomplete adjuvant
after 2 weeks. It was immunized into BALB/c mice (Charles River) 2
times with Freund incomplete adjuvant every week. After the immu-
nizations, we removed the spleen from the mice and hybridized it
with mouse myeloma cells X63-Ag 8.653 as a fusion partner. We gen-
erated monoclonal antibodies up to 36 clones, and ﬁnally selected the
best 2 monoclonal antibodies named 26A1 MoAb and 31A1 MoAb26A1 31A1 Flag M2
25.7- 
17.4- 
Fig. 2. Demonstration of the speciﬁcities of anti-human HTGL mouse monoclonal IgGs
by western blotting. For immunoblotting, 5 μl conditioned medium of human HTGL
Full-Flag/CHO 8A4 was used for 12.5% SDS–PAGE and transferred to nitrocellulose
membrane (Bio-Rad). The membrane was incubated with 2 μg of 26A1 MoAb or
31A1 MoAb followed by incubation with secondary antibody conjugated with horse-
radish peroxidase.
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Fig. 3. Demonstration of the speciﬁcities of anti-human HTGL mouse monoclonal IgGs
by immunoprecipitation–immunoblotting analysis. The supernatant obtained from the
human HTGL Full-Flag/CHO 8A4 Integra cells (Lanes 1–3) and pre-heparin (Lanes 4–6)
or post-heparin plasma (Lanes 7–9) pretreated with 0.1% Tween20-PBS were used in
this demonstration. The immunoprecipitation is shown with 26A1 (Lanes 2, 5, 8) or
31A1 (Lanes 3, 6, 9) or mouse IgG (Lanes 1, 4, 7 as negative control), respectively.
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For testing the cross-reactivity of the ELISA with other lipase mem-
bers including lipoprotein lipase (LPL) and endothelial lipase (EL),
we obtained recombinant human LPL protein from BioVendor and
generated recombinant EL as we previously reported [12].2.3. HTGL sandwich ELISA
Each well of microtiter plates (96 wells) was coated with 100 μl of
100 mmol/l concentrated carbonate buffer (pH 9.5) containing 0.25 μg
puriﬁed 31A1 mouse monoclonal IgG followed by incubation overnight
at 4 °C. The plates were then washed with PBS-T and blocked with
200 μl of 1% (wt/vol) BSA in PBS containing 0.05% NaN3/well overnight
at 4 °C. After washing 2 times with PBS-T, 100 μl of both the serially di-
luted standard of recombinant human HTGL-471 and the 8-fold plasma
sampleswith 1% BSA in PBS-Twas added into eachwell of the coatedmi-
crotiter plates in duplicate and incubated overnight at 4 °C. After wash-
ing 4 times with PBS-T, 100 μl of HRP-conjugated 26A1 mouse IgG Fab′
was added into each well and the samples were incubated for 30 minSTD (ng/mL)
30. 2.600
15. 1.165
7.5 0.554
3.75 0.266
1.88 0.130
0.94 0.067
0.47 0.035
0 0.007
Fig. 4. Typical standard curves of HTGL concentration measured by the sandwich ELISA. Reco
1.88, 0.94 and 0.47 ng/ml in the ELISA.at 4 °C. The wells were washed 8 times with PBS-T and 100 μl of
tetramethyl benzidine solution (Kem-En-Tec) was added into each
well as a substrate followed by incubation in the dark for 30 min at
room temperature. The reaction was stopped by adding 100 μl of
0.5 mol/l H2SO4. We measured absorbance of the solution at 450 nm
by means of an ELISA reader (E-Max; Molecular Devices). For assessing
the intra- and inter-assay precisions of the ELISA, we established 3 QC
samples covering the high, middle and low ranges of the calibration
curves. We determined intra-assay precision by 24 repeated measure-
ments of each QC sample in a plate and inter-assay precision was deter-
mined by assessing each QC sample across 6 different plates with
quintuple wells. Additionally, for assessing the recovery rate in blood
samples, different concentrations of recombinant human HTGL-471
added into samples were measured and the recovery rate was validated
as the difference between the measured concentration and the theoreti-
cal concentration. The analytical limit of quantiﬁcation of this system
was determined on the basis of the guidelines provided by the Clinical
and Laboratory Standards Institute (CLSI) standard EP17-A evaluation
protocols.
The ELISA assay system was ﬁnally designed as an ELISA kit
(Immuno-Biological Laboratories).2.4. Immunoblotting and immunoprecipitation–immunoblotting
We analyzed the supernatant obtained from human HTGL Full-
Flag/CHO 8A4 Integra cells by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE) followed by staining it with
Coomassie Brilliant Blue. For immunoblotting, 5 μl conditioned medi-
um of human HTGL Full-Flag/CHO 8A4 was used for 12% SDS–PAGE
and transferred to nitrocellulose membrane (Bio-Rad). The mem-
brane was incubated with 2 μg of the 26A1 MoAb or 31A1 MoAb
followed by incubation with secondary anti-mouse IgG antibody
conjugated with horseradish peroxidase (HRP) (1:4000, Immuno-
Biological Laboratories).
We also assessed the reactivity of the antibodies by immunopre-
cipitation–immunoblotting. The supernatant obtained from either
the human HTGL Full-Flag/CHO 8A4 Integra cells, pre-heparin or
post-heparin plasma pretreated with 0.1% Tween20-PBS was incubat-
ed with 2 μg of either 26A1 MoAb, 31A1 MoAb or mouse IgG (as neg-
ative control) and then it was added into Protein-G Sepharose (GE
Healthcare Japan). After further incubation, the supernatant was
centrifuged and the resulting pellet was washed 3 times with 500 μl
of TNE buffer (10 mmol/l Tris–HCl, pH 7.8, 150 mmol/l NaCl,
1 mmol/l EDTA, 1% Nonidet P-40). The pellet was subsequently
lysed and we performed immunoblot analysis using biotinylatedAbsorbance at OD 450
mbinant HTGL-471 as a standard was assayed at the concentrations of 30, 15, 7.5, 3.75,
Table 2
Validation results.
Assay value (ng/ml) S.D. (ng/ml) C.V. (%) n
1. Intra-assay reproducibility
13.8 0.71 5.1 24
3.4 0.17 5.0 24
1.2 0.07 6.1 24
2. Inter-assay reproducibility
14.1 0.96 6.8 6
3.4 0.15 4.6 6
1.2 0.08 7.0 6
3. Speciﬁcity test
Human HTGL 100%
Human LPL b0.1%
Human EL b0.1%
204 K. Miyashita et al. / Clinica Chimica Acta 424 (2013) 201–20626A1 MoAb followed by HRP-conjugated streptavidin system. We
visualized the HTGL signal using an ECL reagent (GE Healthcare,
Piscataway, NJ).
2.5. Other method
LPL and HTGL activities were measured using the method we previ-
ously reported [10,11]. Brieﬂy, lipase activities were assayed using
dioleylglycerol solubilized with detergent and measuring the increase
in absorbance at 546 nm (subwave length; 660 nm) due to the produc-
tion of quinonediimine dye. Automated assay of lipase activity was
performed with a Model 7080 Hitachi automatic clinical analyzer. EL
concentration using the sandwich ELISAwasmeasured as we previously
reported [12].
2.6. Preparation of blood samples
The investigation conformed to the principles outlined in the Decla-
ration of Helsinki. The UC Davis Institutional Review Board approved
the experimental protocol and subjects provided informed consent to
participate in the study. We collected PHP samples from overweight
and obese participants in a nutritional research study conducted at
the University of California, Davis Clinical and Translational Science
Center's Clinical Research Center as described previously [13].
The clinical proﬁles of the subjects in this study are shown in
Table 1. The activity of HTGL in the plasma samples was measured
as described and previously reported [11]. PHP was obtained at
10 min after heparin (50 units/kg) was injected. The sera and plasma
were immediately separated and kept frozen at −80 °C until assay.A B
0
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Fig. 5. Dilution linearity of sample materials for the assay. Doubling dilution of original solut
ture of condition medium (A) (or post-heparin plasma (B)) and standard HTGL (original coPlasma concentrations of HDL-C, LDL-C and TG were measured enzy-
matically using kit from Sekisui (Tokyo, Japan).2.7. Statistical analysis
The data was analyzed with Dr. SPSS II (SPSS, Chicago, IL). Quantita-
tive variables are reported as mean ± standard deviation values. The
statistical signiﬁcance of difference was determined by the Mann–
Whitney U test. Pearson's correlation coefﬁcients (r-value) were deter-
mined and single linear regression analysis was performed to detect as-
sociations between variables. A p b 0.05 was considered statistically
signiﬁcant.3. Results
3.1. Identiﬁcation of recombinant human HTGL and characterization of
antibodies against human HTGL
We generated a pair of monoclonal antibodies named 26A1 and
31A1 that exhibited a highly speciﬁc reactivity with the HTGL protein
derived from human HTGL-471/CHO 3B1 stable transfectant. Immuno-
blotting revealed a strong signal against 65-kDa mature HTGL protein
(Fig. 2). To conﬁrm whether the antibodies had the ability to react
with native HTGL in aqueous conditions, we performed an immunopre-
cipitation–immunoblotting analysis. Both 26A1 MoAb and 31A1 MoAb
were able to immunoprecipitate HTGL originated from the conditioned
medium of human HTGL-471/CHO 3B1 stable transfectant (Fig. 3).3.2. Speciﬁcity, recovery and imprecision of the ELISA
Both 26A1 MoAb and 31A1 MoAb showed highly speciﬁc reactiv-
ity with HTGL protein. Thus, we decided to use them for developing
the new sandwich ELISA system. The standard dose–response curve
for the HTGL ELISA system exhibited a linear shape when it was plot-
ted on a log/log scale over a range from 0.47 to 30.0 ng/ml (Fig. 4). Al-
though HTGL has a 53% and 41% amino acid sequence homology with
LPL and EL [14], the cross-reactivity of this ELISA against human LPL
and EL was less than 0.1% (The data is not shown.). Imprecision was
determined with 3 supplemented QC controls (high, middle and
low). The CVs of intra-assay imprecision were exhibited as 5.1% in
the high, 5.0% in the middle and 6.1% in the low controls (Table 2).
Additionally, the inter-assay results for the CVs were 6.8% in the
high, 4.6% in the middle and 7.0% in the low controls. Thus, we can
consider the ELISA system to be reliable concerning imprecision.0
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Dilution (1; doubling diluted Post Heparin Plasma 
with 15 ng/mL of standard added) 
Dilution linearity of Post Heparin Plasma*
ion with 15 ng/ml of standard added samples were deﬁned as dilution rate 1. The mix-
ncentration 15 ng/ml) was diluted as indicated in x-axis in the ﬁgure.
Table 3
Dilution linearity of post-heparin plasma without standard HTGL added for the assay.
Dilution rate
of post heparin
plasma
Dilution 1; doubling
diluted post heparin
plasma
HTGL
concentration
ng/ml
2 1 47.34
4 0.5 46.58
8 0.25 24.12
16 0.125 10.98
32 0.0625 5.49
64 0.03125 2.88
128 0.015625 1.51
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As shown in Fig. 5, a good linearity was shown with culture medi-
um of recombinant HTGL (15 ng/ml of standard added) and doubled
with diluted medium. In contrast, a poor linearity was shown with
PHP (15 ng/ml of standard added) when it was diluted less than 16
fold, which has different matrix from culture medium, and this indi-
cates that those specimens need to be diluted at least 16 fold to obtain
reliable results.
We also investigated dilution effect of PHP without standard HTGL
being added on measured HTGL concentration (Table 3). This data0.0
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Fig. 6. Correlation between HTGL concentration and other plasma proteins in post-heparin p
RLP-TG and EL concentration in PHP from 123 human subjects. The values in the upper colu
tration assay values.also shows that PHP need to be diluted at least 16 fold to obtain reli-
able results in clinical use.
3.4. Correlation of HTGL concentration to lipids and lipoproteins
HTGL concentration in PHP from 124 human subjects was 172 ±
147 ng/ml with a range of 42 to 1200 ng/ml. No patients had an
HTGL concentration below the limit of quantiﬁcation.
HTGL concentration had a strong correlation with HTGL activity
measured by the method we previously reported (Fig. 6). An inverse
correlation was indicated in HTGL concentration with serum HDL-C
(n = 123, p = 0.011, r = −0.23; Fig. 6) while having no correlation
with LDL-C, sdLDL, TG, RLP-C or RLP-TG (Fig. 6). Positive correlation
was observed between HTGL and EL concentration (n = 122, p =
0.013, r = −0.22; Fig. 6).
4. Discussion
We generated speciﬁc HTGL monoclonal antibodies, 26A1 MoAb
and 31A1 MoAb against recombinant human HTGL and we used 2 of
them for establishing a sandwich ELISA system for quantiﬁcation of
human HTGL protein mass in PHP. The immunoblot and immunopre-
cipitation–immunoblot analysis were demonstrated and the obtained
monoclonal antibodies speciﬁcally detected human HTGL.0.0
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lasma. We assayed HTGL concentration, HTGL activity, TG, HDL-C, LDL-C, sdLDL, RLP-C,
mn show the correlation coefﬁcient between the other assay values and HTGL concen-
206 K. Miyashita et al. / Clinica Chimica Acta 424 (2013) 201–206Previously, Nishimura et al. [9] reported a sandwich ELISA system
for measuring human HTGL in PHP using 2 distinct monoclonal anti-
bodies established for speciﬁcally detecting puriﬁed HTGL in PHP.
The average HTGL concentration in PHP obtained from 64 healthy
subjects measured by their ELISA system was reported at around
2000 ng/ml. Compared with their results, our average HTGL concen-
tration in PHP using the 2 distinct monoclonal antibodies, 26A1
MoAb and 31A1 MoAb, speciﬁcally detecting puriﬁed HTGL obtained
from cultured media of CHO cells transfected with HTGL cDNA,
showed as 172 ng/ml, which is less than 1 out of 10 values previously
reported by Nishimura et al. In relation to this fact, the detection range
of their methodwas 40–800 ng/ml of HTGL protein, whereas that of the
present ourmethodwas 0.47–30 ng/ml.We are not certain of the exact
reason why HTGL concentration measured by our method was much
lower than the measurement previously reported by Nishimura et al.
One possibility is that thematerials for immunizingmice for generating
themonoclonal antibodies in ourmethod could bemuch purer than the
method previously reported by Nishimura et al. since the cultured
media for HTGL cDNA stable transfectant may contain much larger
amounts of HTGL protein than PHP.
An inverse correlation of HTGL concentration against HDL-C was
observed in this study. It is consistent with previous reports in that
it is showing the polymorphism of the HTGL gene causing lowered
HTGL activity, which was associated with higher HDL-C concentration
[15–17]. It should be noted that this is the ﬁrst study investigating the
correlation between HTGL and EL, both of which are considered to be-
long to the same gene family. The clinical signiﬁcance of this relation
remains as an outstanding issue but this ﬁnding may suggest that
these 2 lipolytic enzymes may be regulated at least in part by com-
mon factors. Several studies show that EL is increased in metabolic
syndrome and it is observed by using inﬂammation markers, one of
which shows inﬂammation up-regulates EL [18,19]. In relation to
this fact, it is reported that there is a weak but signiﬁcant inverse cor-
relation between EL and adiponectin levels [20].
However, studies including our own case show that inverse corre-
lations exist between adiponectin levels and HTGL activity [21,22].
Moreover, it is recognized that HTGL activity is increased in metabolic
syndrome or insulin resistance state [23–25]. These previous ﬁndings
suggest that there is a similarity between changes in EL and HTGL in
metabolic disorders and support our present ﬁnding that that positive
correlation was observed between EL and HTGL concentration.
In conclusion,wedeveloped a sandwich ELISAusing newly generated
monoclonal antibodies that speciﬁcally detect human HTGL in both PHP
and culturedmedia of CHO transfectedwith HTGL cDNA. The conditions,
such as the limits of quantiﬁcation, and the range of linearity and impre-
cision for HTGL quantiﬁcation, were suitable for both experimental and
clinical uses. From the study of a healthy reference HTGL range in PHP,
we found that its concentrations were approximately between 42 and
1200 ng/ml. It is possible that patients with low HTGL and high plasma
HTGL concentrations associated with high or low HDL-C concentrations
will be identiﬁed by measuring HTGL concentration using this new
assay system. Using a combination of this assay system with an HTGL
activity assay system identiﬁes defective types of HTGL deﬁciency. As de-
scribed above, this method could be useful for further clinical studies for
measuring HTGL concentration in PHP.
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